Investing in people
Lux Capital invests in emerging science and technology ventures at the outermost edges of what is possible.
We partner with iconoclastic inventors challenging the status quo and the laws of nature to bring their futuristic ideas to life.
Play Video Discover LUXOur Companies
Want to know what the future will look like? Spend some time with our companies. You might meet a genetic engineer programming matter at the molecular level; a biologist and electrical engineer designing a new surgical robot; an astrophysicist launching rockets into space; or a materials scientist making circuits using a technique lifted from once-classified government programs.
-
AevaA new sensing paradigm for autonomous machines.
-
Auris Health
Auris Health is an ambitious robotics company based in Silicon Valley. Auris was acquired for up to $6.1B by Johnson & Johnson in 2019.
-
CTRL-labs
CTRL-labs is changing the way we interact with computers. CTRL-labs was acquired by Facebook in 2019.
-
Desktop Metal
Desktop Metal enables high-speed, high-performance, 3D metal printing at production scale. The company listed publicly [NYSE: DM] in 2020.
-
Latch
Latch is building the first universal smart-access platform. The company’s mission is to enable flexible, seamless and secure digital access to physical spaces.
-
Matterport
Matterport is the world’s most powerful all-in-one 3D data platform lets you turn a space into an accurate and immersive digital twin.
-
Recursion Pharmaceuticals
Recursion Pharma is combining high-throughput experimental biology, bioinformatics, and machine learning to rapidly identify new indications for many known drugs and shelved assets.
-
Saildrone
Saildrone collects valuable ocean data using a fleet of unmanned, autonomous sailing drones.
Our team is willing to take a chance on something other investors do not see.
We are neuroscientists, chemists, data scientists, computational biologists, economists, electrical engineers, machine-learning hackers and philosophers. We get fired up when audacious experimentation leads to heresy and reinvention.
News & Insights
Why More Startups And VCs Are Finally Pursuing the Menopause Market: ‘$600B Is Not ‘Niche’’
Deena Shakir-
January 22, 2021
Firm Culture, Solving the Diversity Issue, and How Portfolio Management is a Team Sport
-
January 21, 2021
To Improve The Real World, Simulate It
-
January 21, 2021
Lux leads Plexium’s $35M Series A in the new protein-degradation space
-
January 21, 2021
Our Investment in Plexium: Bringing Intelligent Design to Therapeutic Protein Degraders
-
January 21, 2021
Plexium Announces $35M Financing to Advance Pipeline of Novel Protein Degraders